WATCH ON-DEMAND
With the proliferation of digital innovations, accessible data, and artificial intelligence, the time seems ripe for innovations to disrupt clinical trials. Despite these opportunities, trials today seem confounded by stalled recruitment, overwhelming volumes of data, and stretched resources. What are the greatest opportunities to remove these persistent barriers, and how can biotech agility outpace legacy pharma in adoption? From digitization to decentralization to automation and beyond, join Craig Lipset of Clinical Innovation Partners to explore how we modernize the clinical trial future patients deserve.
Many new biotech companies are formed by in-licensing therapies from the Asia-Pacific region, requiring the complex transfer and translation of thousands of clinical records. Listen to Jon Weiss, co-founder and chief innovation officer at Basis Bio, as he discusses how integrating Egnyte for Life Sciences with Smartsheet streamlines the process, ensuring accurate and efficient record management.
In quality teams, a centralized and standardized process for managing quality control tasks is essential to driving efficiency across your organization. Join Sharon Reinhard, President of Clinical Compliance Solutions at Neuren Therapeutics, as she explores the multifaced journey of adopting Egnyte's Controlled Documents Module as an electronic Quality Management System (eQMS). She will highlight the challenges and successes encountered, showcasing how Neuren transformed their quality control process with Egnyte.
Emerging biotech companies face a critical challenge: managing complex data and processes effectively. Join Daniel Dacey, Founder and CEO of Dovetail Biopartners, as he highlights the impacts of data silos on today's biotechs and how implementing foundational data governance practices can improve operational and scientific excellence to support better clinical outcomes.
Many biotech companies struggle with managing massive amounts of data without an established governance process. Join Dr. Rebecca Carazza as she discusses how Nimbus Therapeutics addresses the complexity of managing over a decade of accumulated unstructured data by leveraging Egnyte to transform its data governance collaboration. During her presentation, Dr. Carazza will also highlight some key challenges encountered during this transition and the strategies Nimbus Therapeutics is implementing to overcome them.
Artificial intelligence is reshaping data management across regulated industries, and life sciences is no exception. In this session, Egnyte’s experts will share our vision for AI in life sciences, highlighting how our secure, purpose-built AI engines are enhancing compliance, governance, and collaboration without compromising data privacy. We will explore the evolution of Egnyte’s machine learning models, our commitment to client data security, AI’s growing role across regulated industries, and the potential of AI-driven regulatory intelligence for clinical trials.
In today’s dynamic biotech environment, success requires navigating an intricate web of science, technology, markets, and regulation—all while pushing the boundaries of innovation. This panel brings together leading CSOs and industry experts to discuss how they balance high-risk, high-reward research with commercialization strategies, talent retention, and regulatory navigation. Join us to explore how emerging technologies, strategic partnerships, and evolving funding models are shaping the future of biotech and how organizations can move efficiently from discovery to patient impact.
Efficient clinical workflows are key to accelerating drug development while ensuring compliance and data integrity. Join this session, where Egnyte experts will showcase our latest innovations in automation, AI-driven actions, eTMF classification, controlled document management, and content request and collection. With Egnyte’s intelligent automation and compliance capabilities, clinical teams can reduce manual effort, improve accuracy, and streamline document workflows, transforming clinical operations for greater efficiency.
In the highly regulated biotech industry, ensuring compliance while maintaining operational efficiency is essential for success. This session will feature Egnyte experts showcasing our latest capabilities to support compliance assessment and automation, remediation of compliance risks, and enhanced eTMF management, helping biotech organizations navigate regulatory complexities with greater ease, ensuring data integrity, inspection readiness, and streamlined workflows.
As we wrap up the 2025 Egnyte Life Sciences Summit, please join us as we reflect on the key insights, innovations, and strategies shared throughout the day. This session will highlight what Egnyte is doing right now to help firms enhance collaboration with sponsors, CROs, and regulatory teams. We will also discuss our commitment to ensuring compliance with ICH E6(R3), FDA 21 CFR Part 11, and GxP regulations and explore how to prepare for the next wave of AI-powered intelligence.